A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations